Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Bullboard - Stock Discussion Forum Medipharm Labs Corp T.LABS

Alternate Symbol(s):  MEDIF

MediPharm Labs Corp. is a Canada-based full-service pharmaceutical company. The Company specializes in the development and manufacture of purified, pharmaceutical-quality cannabis concentrates, active pharmaceutical ingredients (API) and advanced derivative products. Through its wholesale and white label platforms, the Company formulates, develops (including through sensory testing), processes,... see more

TSX:LABS - Post Discussion

Medipharm Labs Corp > Q4 and Year End
View:
Post by Starkicker on Mar 31, 2023 10:11am

Q4 and Year End

I'm a little surprised the needle didn't move upwards a little bit after earnings.
Comment by subaru1 on Mar 31, 2023 11:05am
Starkicker, give me any raisons why the stock would have moved after these number which are very disapointing and all the blabla is the same story we hear since too long. The market gives at Labs what it worth no more and we are still lucky to be at $0,075, i would not be surprised that we touch $0,06 soon.
Comment by subaru1 on Mar 31, 2023 11:14am
and don't forget the dilution that is coming with Vivo acquisition
Comment by Starkicker on Mar 31, 2023 12:31pm
I'll give you a few reasons. Outright ownership of assets, debt free, $24M in cash, reduced cash burn, increasing revenue, and expectations of positive EBITDA and cash flow first half of 2024. The Arrangement with VIVO will be a one step back two steps forward situation, and the transition from B2B sales is done, the anchor chain is broken. Cleared for takeoff.
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities